Peripheral Vascular Devices – Market Insights – United States

The US PV device market is currently seeing a high volume of innovation, with adoption of new, premium technologies and expanding indication approvals for existing devices supporting the market. Although some procedures will face barriers due to a push for cost-effective PV interventions, favorable reimbursement decisions are supporting uptake of other novel technologies.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PV devices in the US from 2019 through 2033.

The adoption of premium-priced devices will support US PV device market growth.

How is the standard of care changing in PV device space as new technologies emerge?

How is reimbursement affecting the adoption of different devices and procedures?

What limitations do new technologies face in terms of approved indications?

The launch of innovative devices for treating BTK lesions will bolster the US PV device market going forward.

What are the device types and technological innovations being evaluated to address unique challenges of treating BTK lesions?

How will the entry new drug-eluting technologies, including BRS, affect to the adoption of endovascular techniques in the infrapop indication?

Which competitors are standing to benefit from new devices, and how will it shape the market going forward?

Several key players in the PV device market have expanded their presence in the US market through acquisition and partnerships.

Which key players in the PV device market are involved in acquisitions and partnerships, and how will these developments impact key players’ shares in the future?

How will the key players that completed acquisitions adjust their marketing strategies to optimally utilize their expanded PV device portfolios?

Continued cuts to the reimbursement rates in certain sites of service and procedure types will result in a shift in site for some procedure volumes.

What new reimbursement updates released by the CMS will have an impact on PV device uptake?

How have recent reimbursement policies influenced the site-of-service penetration for different PV procedure types?